Current reports
6-K
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
26 Apr 24
6-K
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
25 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4 Apr 24
6-K
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
6 Mar 24
6-K
Interim condensed consolidated financial statements of
14 Feb 24
6-K
Current report (foreign)
13 Feb 24
6-K
Notice of Change of Auditor
24 Jan 24
6-K
Medicenna Announces Appointment of New Auditor
12 Jan 24
Registration and prospectus
AW
Withdrawal of amendment
22 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Apr 24
F-3/A
Shelf registration (foreign) (amended)
16 Apr 24
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
16 Apr 24
25-NSE
Exchange delisting
20 Nov 23
F-3
Shelf registration (foreign)
17 Feb 23
SUPPL
Supplemental materials (foreign)
10 Aug 22
SUPPL
Supplemental materials (foreign)
9 Aug 22
SUPPL
Supplemental materials (foreign)
8 Aug 22
SUPPL
Supplemental materials (foreign)
30 Dec 20
Proxies
No filings